Based on the binding site shared between bortezomib and carfilzomib, PSMB5 mutations in the β5 subunit were predicted be a hotspot for PI resistance, and bortezomib-adapted MM cell lines have shown mutations there [76,77]. The gene discussed is PSMB5; the disease is Miyoshi myopathy.